Summary of characteristics of 267 patients at diagnosis
| Characteristics . | Number/value . | % . | Range . |
|---|---|---|---|
| Age, median, years | 63.0 | 29-94 | |
| Sex | |||
| Female | 125 | 47 | |
| Male | 142 | 53 | |
| Clinical subtype | |||
| Chronic type | 149 | 56 | |
| Smoldering type | 118 | 44 | |
| Admitted to | |||
| Hematology Department | 184 | 69 | |
| Dermatology Department | 83 | 31 | |
| Neutrophil count, median, ×109/L | 4.1 | 0.0-36.6 | |
| Lymphocyte count, median, ×109/L | 4527 | 480-80 567.5 | |
| Abnormal lymphocyte count, median, ×109/L | 1554 | 0.0-78 826 | |
| Hemoglobin level, median, g/dL | 13.6 | 4.2-17.7 | |
| Platelet count, median, ×109/L | 220 | 63-560 | |
| Serum total protein, median, g/dL | 7.1 | 4.8-8.9 | |
| Serum albumin, median, g/dL | 4.2 | 2.3-5.4 | |
| BUN, median, mg/dL | 13.4 | 3.5-70.0 | |
| LDH, median, IU/L | 246 | 122-926 | |
| LDH > ULN, % | 134 | 50 | |
| Soluble IL-2R, median, U/mL | 2796 | 192-162 000 | |
| Increased CRP present | 83 | 31 | |
| Stage | |||
| I-II | 29 | 11 | |
| III-IV | 238 | 89 | |
| ECOG performance status | |||
| 0-1 | 248 | 93 | |
| 2-4 | 19 | 7 | |
| B symptoms present | 26 | 10 | |
| Number of lymph node lesions, median, range | 0 | 0-11 | |
| Number of extranodal sites, median, range | 1 | 0-4 | |
| Total number of involved lymph nodes and extranodal lesions, median, range | 4 | 0-13 | |
| Bone marrow involvement present | 39 | 15 | |
| Liver involvement present | 4 | 2 | |
| Spleen involvement present | 13 | 5 | |
| Skin lesions present | 162 | 61 | |
| Lung involvement present | 12 | 4 |
| Characteristics . | Number/value . | % . | Range . |
|---|---|---|---|
| Age, median, years | 63.0 | 29-94 | |
| Sex | |||
| Female | 125 | 47 | |
| Male | 142 | 53 | |
| Clinical subtype | |||
| Chronic type | 149 | 56 | |
| Smoldering type | 118 | 44 | |
| Admitted to | |||
| Hematology Department | 184 | 69 | |
| Dermatology Department | 83 | 31 | |
| Neutrophil count, median, ×109/L | 4.1 | 0.0-36.6 | |
| Lymphocyte count, median, ×109/L | 4527 | 480-80 567.5 | |
| Abnormal lymphocyte count, median, ×109/L | 1554 | 0.0-78 826 | |
| Hemoglobin level, median, g/dL | 13.6 | 4.2-17.7 | |
| Platelet count, median, ×109/L | 220 | 63-560 | |
| Serum total protein, median, g/dL | 7.1 | 4.8-8.9 | |
| Serum albumin, median, g/dL | 4.2 | 2.3-5.4 | |
| BUN, median, mg/dL | 13.4 | 3.5-70.0 | |
| LDH, median, IU/L | 246 | 122-926 | |
| LDH > ULN, % | 134 | 50 | |
| Soluble IL-2R, median, U/mL | 2796 | 192-162 000 | |
| Increased CRP present | 83 | 31 | |
| Stage | |||
| I-II | 29 | 11 | |
| III-IV | 238 | 89 | |
| ECOG performance status | |||
| 0-1 | 248 | 93 | |
| 2-4 | 19 | 7 | |
| B symptoms present | 26 | 10 | |
| Number of lymph node lesions, median, range | 0 | 0-11 | |
| Number of extranodal sites, median, range | 1 | 0-4 | |
| Total number of involved lymph nodes and extranodal lesions, median, range | 4 | 0-13 | |
| Bone marrow involvement present | 39 | 15 | |
| Liver involvement present | 4 | 2 | |
| Spleen involvement present | 13 | 5 | |
| Skin lesions present | 162 | 61 | |
| Lung involvement present | 12 | 4 |
BUN, blood urea nitrogen; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; IL-2R, interleukin-2 receptor; ULN, upper limit of normal.
The sIL-2R level by picogram per milliliter may be converted to units per milliliter, using the formula: value (pg/mL) × 0.113.